Rifampicin-d8

OC(C(/C=N/N1C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C1([2H])[2H])=C(NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@@H](C)[C@H]2O)O)C)=O)C(O)=C3C(O)=C4C)=C3C5=C4O[C@](C)(O/C=C/[C@@H]([C@H]([C@@]([C@@H]2C)([H])OC(C)=O)C)OC)C5=O

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6 (2) :169-74.|[3]Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979; (2) :333-7.|[4]Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006; (8) :58-61.|[5]Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55 (4) :528-34. Epub 2005 Mar 2.